Pharma Journalist -

AbCellera announced that it has closed a US$105 million Series B financing. The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes…
Read More...

EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, and Immunochina, a company dedicated…
Read More...

SMi reports: Envisagenics will be presenting latest case study on RNA-therapeutics for Triple Negative Breast Cancer Envisagenics is a spin out of the world-renowned Cold Spring…
Read More...

Thermo Fisher Scientific, the world leader in serving science, and Biognosys, a leading developer of next-generation proteomics solutions, announce they are continuing their…
Read More...

Hutchison China MediTech Limited and BeiGene, Ltd. announced that they have entered into a clinical collaboration agreement to evaluate the safety, tolerability and efficacy of…
Read More...

Merck, known as MSD outside the United States and Canada, and Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer, today announced…
Read More...

Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people…
Read More...

Novasep and Lysogene announced the signature of an agreement for the development and manufacturing of LYS-GM101, an AAVrh10-based gene therapy drug candidate for the treatment of GM1…
Read More...

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced that the companies have entered into a…
Read More...

Repare Therapeutics Inc. (“Repare”), a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in…
Read More...